Lafrost10%

Lafrost cream is an over-the-counter topical antiviral indicated for the following use:

• Established/approved use: Treatment of recurrent oral-facial herpes simplex (cold sores/fever blisters) on the lips and around the mouth in otherwise healthy (immunocompetent) adults and adolescents. It is intended to be applied at the earliest sign of an outbreak (tingling, itching, redness, or a bump) to help shorten healing time and duration of symptoms such as pain, burning, and itching.

Lafrost is not indicated for the treatment of cold sores inside the mouth, on the gums, or for genital herpes, and it is not intended for use in immunocompromised individuals without physician guidance.

Each gram of Docosanol cream contains Docosanol 10% w/w as the active ingredient, in a cream base containing excipients such as purified water, mineral oil, propylene glycol, benzyl alcohol, and other emulsifying and stabilizing agents (exact inactive ingredients may vary by manufacturer).

Lafrost is a long-chain saturated aliphatic (22-carbon) fatty alcohol formulated as a 10% topical cream. It is the only FDA-recognized non-prescription topical agent specifically indicated to treat recurrent herpes labialis (cold sores) by targeting the mechanism of viral entry into host cells rather than acting as a direct nucleoside analogue antiviral.

Lafrost is applied directly to the affected area of the lips and face at the first sign of a cold sore and continued until the lesion has healed.

Lafrost belongs to the class of topical antiviral agents, specifically classified as a long-chain saturated fatty alcohol with antiviral activity against herpes simplex virus (HSV) types 1 and 2. Pharmacologically it is distinct from nucleoside analogue antivirals (such as acyclovir) because it does not inhibit viral DNA polymerase.

Mechanism of Action

Docosanol is believed to act by inhibiting fusion between the host cell plasma membrane and the herpes simplex virus envelope. By blocking this fusion step, Docosanol prevents the virus from entering susceptible host cells, which in turn blocks viral replication and the entry of the virus into uninfected cells. Unlike acyclovir and related agents, Docosanol does not inhibit viral DNA polymerase and has no direct virucidal activity.

Pharmacokinetics

When applied topically, Docosanol is minimally absorbed through the skin into the systemic circulation. Because systemic exposure is negligible with normal topical use, clinically significant systemic pharmacokinetic interactions are not expected.

Lafrost cream is for external (topical) use only on the lips and surrounding skin. Apply a small amount using a clean fingertip or applicator, rub in gently, and wash hands afterward. Avoid contact with the eyes and mucous membranes. Do not swallow.

Because Lafrost is applied topically and undergoes minimal systemic absorption, no clinically significant drug-drug interactions have been established. There are no well-verified interactions between Lafrost and orally or systemically administered medicines. Applying other topical products (such as lip cosmetics or other topical medications) to the same area at the same time as Lafrost is not recommended, as this has not been studied and may affect absorption or irritate the skin.

Lafrost cream is generally well tolerated. Reported side effects are usually mild and limited to the application site, and include:

• Headache
• Mild application-site reactions such as redness, itching, dryness, or a burning/stinging sensation
• Rare allergic contact reactions (rash, swelling, itching, or hives), which would warrant stopping use and consulting a physician

Serious adverse effects are uncommon with correct topical use. Any signs of a severe allergic reaction (facial swelling, difficulty breathing, widespread rash) require immediate medical attention.

There are no adequate, well-controlled studies specifically establishing the safety of Lafrost in pregnant or breastfeeding women. Because Lafrost is applied topically and has minimal systemic absorption, systemic fetal or infant exposure is expected to be very low; however, as a general precaution, pregnant or breastfeeding women should use Lafrost only if clearly needed, avoid applying it to or near the nipple area during breastfeeding, and consult a physician or pharmacist before use.

Lafrost is for external use only. The following precautions apply:

• Avoid contact with the eyes; if accidental contact occurs, rinse thoroughly with water.
• Do not apply inside the mouth, on the gums, or to genital lesions.
• Consult a physician if the cold sore does not improve within 10 days of starting treatment, or if symptoms worsen.
• Consult a physician if fever, widespread skin lesions, recurrent outbreaks (more than 6 times a year), or signs of secondary bacterial infection occur, as these may indicate a need for other treatment.
• Discontinue use and seek medical advice if signs of an allergic or hypersensitivity reaction develop (see Contraindications).
• Individuals with a weakened immune system should consult a physician before use, as cold sore management may need to be different in this population.

Lafrost cream is intended for topical use in small amounts, and significant systemic overdose is unlikely with normal use. If a large amount is accidentally ingested, or if excessive application causes severe local irritation or a suspected allergic reaction, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric: Safety and efficacy of Lafrost in children under 12 years have not been established; use only under medical supervision in this age group.

Elderly: No specific dose adjustment is required for elderly patients; general precautions for topical use apply.

Immunocompromised patients: Lafrost has been studied primarily in immunocompetent individuals; immunocompromised patients (e.g., HIV infection, on immunosuppressive therapy) should consult a physician before use, as alternative or prescription antiviral therapy may be more appropriate.

Renal/Hepatic impairment: No dose adjustment is established or generally required given minimal systemic absorption with topical use, but caution and physician consultation are advised in significant impairment.

Lafrost cream should be applied 5 times daily starting at the first sign of a cold sore and continued until the lesion has healed, which is typically achieved within 10 days. If healing is not evident by day 10, treatment should be stopped and a physician consulted.

Docosanol is classified as a topical antiviral / saturated long-chain fatty alcohol used for herpes labialis (cold sores).

Docosanol works by blocking fusion between the host cell membrane and the herpes simplex viral envelope, thereby preventing viral entry into uninfected cells and interrupting the infection and replication cycle. See Pharmacology for full mechanistic detail.

Lafrost 10% cream is approved for use in adolescents 12 years of age and older using the same dosing as adults (apply 5 times daily to the affected area until healed). Safety and efficacy in children younger than 12 years have not been established, and use in this age group should occur only under medical supervision.